Key facts
- Notable investors include Huatai Zijin Investment, Motianshi Investment, Grand Mount Capital, Haier BioMedical, Linghang Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Sanyou Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Sanyou Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sanyou Bio
Provider of biotechnology services intended for the development of novel antibodies. The company offers integrated discovery capabilities, diversified research functions, advanced laboratory platforms, high-capacity screening technologies, and coordinated development workflows that encompass antibody identification, engineering, evaluation, and optimization, enabling patients to receive better and more precise treatment.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 300
- Website
- sanyoubio.com.cn/
- Ownership
- Privately Held (backing)
Sanyou Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sanyou Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sanyou Bio in its N-PORT filings yet. We sweep new filings monthly.